Startseite>>Signaling Pathways>> Microbiology & Virology>> Influenza virus>>Carbodine

Carbodine

Katalog-Nr.GC35606

Carbodin (Carbozyklisches Cytidin) ist ein antivirales Breitbandmittel, das gegen DNA-Viren, (+)RNA-Viren, (-)RNA-Viren, Paramyxo-, Rhabdo- und (+/-)RNA-Viren aktiv ist und auf CTP-Synthetase abzielt der UTP in CTP umwandelt.

Products are for research use only. Not for human use. We do not sell to patients.

Carbodine Chemische Struktur

Cas No.: 71184-20-8

Größe Preis Lagerbestand Menge
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Carbodine (Carbocyclic cytidine) is a broad-spectrum antiviral agent active against DNA viruses, (+)RNA viruses, (-)RNA viruses, paramyxo, rhabdo and (+/-)RNA viruses, targets CTP synthetase that converts UTP to CTP. Carbodine (Carbocyclic cytidine) possesses significant antiviral activity against influenza virus types A0/PR-8/34 and A2/Aichi/2/68 in vitro[1][2].

[1]. De Clercq E, et al. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem Pharmacol. 1990 Jan 15;39(2):319-25. [2]. Shannon WM, et al. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob Agents Chemother. 1981 Dec;20(6):769-76.

Bewertungen

Review for Carbodine

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carbodine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.